Also known as: UACR
Semaglutide improves kidney, survival, and quality-of-life outcomes in type 2 diabetes with CKD, per FLOW trial analyses. Benefits were consistent across cardiovascular and severity subgroups, adding eight full-health days per year.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
